This prospective pilot study showed that the assessment of IL-23 levels at baseline could predict clinical and endoscopic outcomes to ustekinumab therapy in Crohn’s disease. Testing this biomarker before starting a biological therapy could be useful for a personalized choice.
Baseline Assessment of Serum Cytokines Predicts Clinical and Endoscopic Response to Ustekinumab in Patients With Crohn’s Disease: A Prospective Pilot Study
Bertani, Lorenzo;Antonioli, Luca;Fornili, Marco;D'Antongiovanni, Vanessa;Ceccarelli, Linda;Carmisciano, Luca;Mumolo, Maria Gloria;Bottari, Andrea;Pardi, Veronica;Baiano Svizzero, Giovanni;Baglietto, Laura;De Bortoli, Nicola;Bellini, Massimo;Fornai, Matteo;
2024-01-01
Abstract
This prospective pilot study showed that the assessment of IL-23 levels at baseline could predict clinical and endoscopic outcomes to ustekinumab therapy in Crohn’s disease. Testing this biomarker before starting a biological therapy could be useful for a personalized choice.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
